Sia Daneshmand, MD, presented “Updates in Muscle Invasive Bladder Cancer” virtually during the 21st Annual Future Directions in Urology Symposium in August 2020.
How to cite: Daneshmand, Sia. “Updates in Screening: Prostate Cancer Guidelines.” August 10th, 2020. Accessed Dec 2024. https://dev.grandroundsinurology.com/updates-in-muscle-invasive-bladder-cancer/
Summary:
Sia Daneshmand, MD, Associate Professor of Urology and Director of Clinical Research at the University of Southern California, describes the current landscape of muscle invasive bladder cancer treatment, highlighting developments in radical cystectomy and chemotherapy. He observes that while radical cystectomy has long been the gold standard, efforts are being made to preserve reproductive organs in female patients who have low-stage disease. Dr. Daneshmand also notes the significant number of neoadjuvant chemotherapy phase II trials currently underway. While studies examining adjuvant chemotherapy have shown promise, the limitations of these trials necessitate further research. Similarly, research comparing super-extended lymph node dissection (LND) with extended LND have yielded insignificant p-values, but absolute numbers demonstrate a positive upward survival trend over 5 years. Dr. Daneshmand concludes that additional clinical trials will reveal the optimal combination and sequencing of treatment options.
About The 2020 Virtual Future Directions in Urology Symposium
The Future Directions in Urology Symposium was founded 21 years ago to reflect on the current state of the urology community and predict trends in the treatment of urology conditions in the following 5-10 years. This conference brings together experts in the field, including urologists, medical oncologists, radiation oncologists, family practice doctors, researchers, and industry leaders to review current trends and prospects. Dr. Daneshmand presented this lecture during this year’s virtual conference in August 2020.
ABOUT THE AUTHOR
Dr. Siamak Daneshmand earned his medical degree at the University of California, Davis, and completed his residency at the University of Southern California, followed by a two-year Fellowship in Urologic Oncology at the University of Southern California’s Norris Comprehensive Cancer Center. He is currently the Associate Professor of Urology and serves as Director of Clinical Research at the University of Southern California, Keck School of Medicine, and has extensive experience in the management of advanced kidney cancers and prostate cancer.
